Experimental hematology Lab PD Dr. med. Dr. rer. nat. S. Balabanov

Projects

Melanie Balabanov

Telomere Biology in the progression of BCR-ABL-positive leukemia:
Uncovering the role of inflammatory processes and cellular senesence

Telomeres have been shown to inherit a pivotal role in human disease and organismal aging. Short telomeres were found in advanced stages of human neoplasia including chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the oncogenic tyrosine kinase BCR-ABL in hematopoietic stem cells (HSCs). In this project we would like to decipher the role of telomere length in the progression of CML by using the telomerase knockout mouse model (mTR-/-). In particular, we aim to address the impact of cellular senescence as a potent anti-proliferative mechanism against leukemia formation and the role of a newly-discovered inflammatory phenotype that is closely related to telomere shortening.

In collaboration with Prof. Tim H. Brümmendorf, University Hospital Aachen, Department of Hematology/Oncology Aachen, Germany.

Publications

2016

Dyshlovoy SA, Venz S, Hauschild J, Tabakmakher KM, Otte K,  Madanchi R, Walther R, Guzii AG, Makarieva TN, Shubina LK, Fedorov SN, Stonik VA, Bokemeyer C, Balabanov S, Honecker F, Amsberg GV.
Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation.
Proteomics. 2016 Mar 22. (Epub ahead of print)
Pubmed

Weidner CI, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, Bruns H, Balabanov S, Trummer A, Stockklausner C, Höchsmann B, Schrezenmeier H, Wlodarski M, Panse J, Brümmendorf TH, Beier F, Wagner W.
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
Oncotarget. 2016 Mar 8;7(10):10765-72.
Pubmed

 

2015​

Dyshlovoy SA, Menchinskaya ES, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin VI, Silchenko AS, Avilov SA, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin DL, Fedorov SN, Shubina LK, Stonik VA, Balabanov S, Honecker F, von Amsberg G.
The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer.
Int J Cancer. 2015 Dec 22. (Epub ahead of print)
Pubmed

Werner B, Beier F, Hummel S, Balabanov S, Lassay L, Orlikowsky T, Dingli D, Brümmendorf TH, Traulsen A.
Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions.
Elife. 2015 Oct 15;4. (Epub ahead of print)
Pubmed

Dyshlovoy SA, Hauschild J, Amann K, Tabakmakher KM, Venz S, Walther R, Guzii AG, Makarieva TN, Shubina LK, Fedorov SN, Stonik VA, Bokemeyer C, Balabanov S, Honecker F, von Amsberg G.
Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization.
Oncotarget. 2015 Juli10;6(19):17328-41
Pubmed

Pällmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel CH, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S.
Biological Relevance and Therapeutic Potential of the Hypusine Modification System.
J Biol Chem. 2015 Jul 24;290(30):183-60. Epub 2015 Jun 2.
Pubmed

Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf TH, Murthy PV, Balabanov S.
Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
J Proteomics. 2015 Apr 24;119:218-29. Epub 2015 Feb 24.
Pubmed

Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P.
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
Oncology. 2015;89(2):70-8. Epub Mar 11.
Pubmed


 

2014

Sievert H, Pällmann N, Miller KK, Hermans-Borgmeyer I, Venz S, Sendoel A, Preukschas M, Schweizer M, Boettcher S, Janiesch PC, Streichert T, Walther R, Hengartner MO, Manz MG, Brümmendorf TH, Bokemeyer C, Braig M, Hauber J, Duncan KE, Balabanov S.
A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformation.
Dis Model Mech. 2014 Aug 7;7(8):963-76.E pub 2014 May 15.
Pubmed

Lohmann F, Sachs M, Meyer TN, Sievert H, Lindenmeyer MT, Wiech T, Cohen CD, Balabanov S, Stahl RA, Meyer-Schwesinger C.
UCH-L1 induces podocyte hypertrophy in membranous nephropathy by protein accumulation.
Biochim Biophys Acta. 2014 Jul;1842(7):945-58. Epub 2014 Feb 28.
Pubmed

Balabanov S, Braig M, Brümmendorf TH.
Current aspects in resistence against tyrosine kinase inhibitors in chronic myelogenous leukemia.
Drug Discov Today Technol. 2014 Mar;11:89-99
Pubmed

Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf TH.
A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.
Leukemia. 2014 Mar 7. (Epub ahead of print)
Pubmed

2013

Honecker F. Rohlfing T, Harder S, Braig M, Gillis Aj, Glaesener S, Barett C, Bokemeyer C, Buck F, Brümmendorf TH, Looijenga LH, Balabanov S.
Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines.
J. Proteomics. 2013 Nov. 22; 96C:300-313.
Pubmed

Dyshlovoy SA, Venz S, Shubina LK, Fedorov SN, Walther R, Jacobsen C, Stonik VA, Bokemeyer C, Balabanov S, Honecker F.
Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer.
J Proteomics. 2013 Nov. 21; 96C:223-239.
Pubmed

Balabanov S, Wilhelm T, Venz S, Keller G, Scharf C, Pospisil H, Braig M, Barett C, Bokemeyer C, Walther R, Brümmendorf TH, Schuppert A.
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
PLoS One. 2013; 8(1). Epub 2013 Jan 9.
Pubmed

Balabanov S, Evans CA, Abraham SA, Pellicano F, Copland M, Walker MJ, Whetton AD, Holyoake TL.
Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.
Proteomics 2013 Jan;13(1):153-68.
Pubmed


2012

Balabanov S, Evans CA, Abraham SA, Pellicano F, Copland M, Walker MJ, Whetton AD, Holyoake TL.
Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from CML patients.
Proteomics. 2012 Nov 26 (E pub ahead of print)
Pubmed

Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M.
Anti-tumor activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Br J Cancer. 2012 Nov 20; 107 (11): 1153-63.
Pubmed

Preukschas P, Hagel C, Schulte A, Weber A, Lamszus K, Sievert H, Pällmann N, Bokemeyer C, Hauber J, Braig M, Balabanov S.
Expression of Eukaryotic Initiation Factor FA and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies.
PLoS One. 2012; 7 (8).
Pubmed

Martens T, Matschke J, Müller C, Riethdorf S, Balabanov S, Westphal M, Heese O.
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Clin Neurol Neurosurg. 2012 Jun 13. (E pub ahead of print)
Pubmed

Ziegler P, Schrezenmeier H, Akkad J, Brassat U, Vankann L, Panse J, Wilop S, Balabanov S, Schwarz K, Martens UM, Brümmendorf TH.
Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.
Ann Hematol. 2012 Jul; 91 (7): 115-20.
Pubmed

Meyer-Schwesinger C, Dehde S, Sachs M, Mathey S, Arefi K, Gatzemeier S, Balabanov S, Becker JU, Thaiss F, Meyer TN.
Rho-kinase inhibition prevents proteinuria in immune-complex mediated anti-podocyte nephritis.
Am J Physiol Renal Physiol. 2012 Jul 18. (E pub ahead of print)
Pubmed

Sievert H, Venz S, Platas-Barradas O, Dhople VM, Schaletzky M, Nagel CH, Braig M, Preukschas M, Pallmann N, Bokemeyer C, Brümmendorf TH, Portner R, Walther R. Duncan KE, Hauber J, Balabanov S.
Protein-Protein-Interaction Network Organization of the Hypusine Modification System.
Mol Cell Proteomics. 2012 Aug 10. (E pub ahead of print)
Pubmed

Ziegler P., Chahoud T, Wilhelm T., Pallman N., Braig M., Wiehle V., Ziegler S., Schroder M., Meier C., Kolodzik A., Rarey M., Panse J., Hauber J., Balabanov S., Brummendorf TH
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Invest New Drugs 2012.
Pubmed

Ummanni R., Barreto F., Venz S., Scharf C., Barret C., Mannsperger H.A., Brase J.C., Kuner R., Schlomm T., Sauter G., Sultmann H., Korf U., Bokemeyer C., Walther R., Brummendorf TH, Balabanov S.
Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
J. Proteome Res 2012.
Pubmed

Dyshlovoy S.A., Naeth I., Venz S., Preukschas M., Sievert H., Jacobsen C., Shubina L., Gesell Salazar M., Scharf C., Walther R., Krepstakies M., Priyadarshini P., Hauber J., Fedorov S.N., Bokemeyer C., Stonik V.A., Balabanov S., Honecker F.
Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaolid with antiproliferative activity.
J Proteome Res 2012.
Pubmed

2011

Schaletzky M., Platas Barradas O., Sievert H., Balabanov S., Zeng A.P., Portner R.
Cultivation strategies of a BA/F3 cell line for fundamental cell research.
BMC Proc 2011, 5 Suppl 8, P 48.
Pubmed

Werner, B., Lutz, D., Brummendorf, T. H., Traulsen, A., Balabanov, S. Dynamics of Resistance Development to Imatinib under Increasing Selection Pressure: A Combination of Mathematical Models and In Vitro Data.
PLoS One 2011, 6, e28955.
Pubmed

Ummanni, R., Mundt, F., Pospisil, H., Venz, S., Scharf, C., Barett, C., Falth, M., Kollermann, J., Walther, R., Schlomm, T., Sauter, G., Bokemeyer, C., Sultmann, H., Schuppert, A., Brummendorf, T. H., Balabanov, S.
Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
PLoS One 2011, 6, e16833.
Pubmed

Ummanni, R., Jost, E., Braig, M., Lohmann, F., Mundt, F., Barett, C., Schlomm, T., Sauter, G., Senff, T., Bokemeyer, C., Sultmann, H., Meyer-Schwesinger, C., Brummendorf, T. H., Balabanov, S.
Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Mol Cancer 2011, 10, 129.
Pubmed

Minner, S., Wittmer, C., Graefen, M., Salomon, G., Steuber, T., Haese, A., Huland, H., Bokemeyer, C., Yekebas, E., Dierlamm, J., Balabanov, S., Kilic, E., Wilczak, W., Simon, R., Sauter, G., Schlomm, T.
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.

 

Prostate 2011, 71, 281-288.
Pubmed

Meyer-Schwesinger, C., Meyer, T. N., Sievert, H., Hoxha, E., Sachs, M., Klupp, E. M., Munster, S., Balabanov, S., Carrier, L., Helmchen, U., Thaiss, F., Stahl, R. A.
Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.
Am J Pathol 2011, 178, 2044-2057.
Pubmed

Meyer-Schwesinger, C., Dehde, S., Klug, P., Becker, J. U., Mathey, S., Arefi, K., Balabanov, S., Venz, S., Endlich, K. H., Pekna, M., Gessner, J. E., Thaiss, F., Meyer, T. N.
Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis.
J Immunol 2011, 187, 3218-3229.
Pubmed

Brassat, U., Balabanov, S., Bali, D., Dierlamm, J., Braig, M., Hartmann, U., Sirma, H., Gunes, C., Wege, H., Fehse, B., Gontarewicz, A., Dikomey, E., Borgmann, K., Brummendorf, T. H., Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Exp Hematol 2011, 39, 66-76 e61-62.
Pubmed

Balabanov, S., Gontarewicz, A., Keller, G., Raddrizzani, L., Braig, M., Bosotti, R., Moll, J., Jost, E., Barett, C., Rohe, I., Bokemeyer, C., Holyoake, T. L., Brummendorf, T. H.
Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
PLoS One 2011, 6, e19164.
Pubmed


2010

Binder, M., Lechenne, B., Ummanni, R., Scharf, C., Balabanov, S., Trusch, M., Schluter, H., Braren, I., Spillner, E., Trepel, M.,
Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells.
PLoS One 2010, 5, e15992.
Pubmed



2009

Benten, D., Keller, G., Quaas, A., Schrader, J., Gontarewicz, A., Balabanov, S., Braig, M., Wege, H., Moll, J., Lohse, A. W., Brummendorf, T. H.Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Neoplasia 2009, 11, 934-944.
Pubmed

2008

Gontarewicz, A., Balabanov, S., Keller, G., Panse, J., Schafhausen, P., Bokemeyer, C., Fiedler, W., Moll, J., Brummendorf, T. H.
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.

 

Leuk Res 2008, 32, 1857-1865.
Pubmed

Gontarewicz, A., Balabanov, S., Keller, G., Colombo, R., Graziano, A., Pesenti, E., Benten, D., Bokemeyer, C., Fiedler, W., Moll, J., Brummendorf, T. H.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Blood 2008, 111, 4355-4364.
Pubmed

Glaesener, S., Honecker, F., Veltman, I. M., Gillis, A. J., Rohlfing, T., Streichert, T., Otto, B., Brummendorf, T. H., Looijenga, L. H., Bokemeyer, C., Balabanov, S.
Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line.
J Proteome Res 2008, 7, 3890-3899.
Pubmed



2007

Mueller, S., Hartmann, U., Mayer, F., Balabanov, S., Hartmann, J. T., Brummendorf, T. H., Bokemeyer, C.
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Invest New Drugs 2007, 25, 519-524.
Pubmed

Drummond, M. W., Balabanov, S., Holyoake, T. L., Brummendorf, T. H.
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.
Stem Cells 2007, 25, 1853-1861.
Pubmed

Beier, F., Balabanov, S.*, Amberger, C. C., Hartmann, U., Manger, K., Dietz, K., Kotter, I., Brummendorf, T. H.
Telomere length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus using multi-color flow-FISH.
Lupus 2007, 16, 955-962. * joint first author
Pubmed


Balabanov, S., Gontarewicz, A., Ziegler, P., Hartmann, U., Kammer, W., Copland, M., Brassat, U., Priemer, M., Hauber, I., Wilhelm, T., Schwarz, G., Kanz, L., Bokemeyer, C., Hauber, J., Holyoake, T. L., Nordheim, A., Brummendorf, T. H.
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Blood 2007, 109, 1701-1711.
Pubmed

2006

Zimmermann, U., Junker, H., Kramer, F., Balabanov, S., Kleist, B., Kammer, W., Nordheim, A., Walther, R.
Comparative proteomic analysis of neoplastic and non-neoplastic germ cell tissue.
Biol Chem 2006, 387, 437-440.
Pubmed

 

Brummendorf, T. H., Balabanov, S.
Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover.
Leukemia 2006, 20, 1706-1716.
Pubmed

 

 

2005

Hartmann, U., Brummendorf, T. H., Balabanov, S., Thiede, C., Illme, T., Schaich, M., Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities.
Haematologica 2005, 90, 307-316.
Pubmed

Hartmann, U. ,Balabanov, S., Ziegler, P., Fellenberg, J., van der Kuip, H., Duyster, J., Lipp, H. P., Bokemeyer, C., Kanz, L., Brummendorf, T. H.
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
Exp Hematol 2005, 33, 542-549.
Pubmed

Beier, F., Balabanov, S., Buckley, T., Dietz, K., Hartmann, U., Rojewski, M., Kanz, L., Schrezenmeier, H., Brummendorf, T. H.
Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH.
Blood2005, 106, 531-533.
Pubmed

Bartolovic, K., Balabanov, S., Berner, B., Buhring, H. J., Komor, M., Becker, S., Hoelzer, D., Kanz, L., Hofmann, W. K., Brummendorf, T. H.
Clonal heterogeneity in growth kinetics of CD34+CD38- human cord blood cells in vitro is correlated with gene expression pattern and telomere length.
Stem Cells 2005, 23, 946-957.
Pubmed

Balabanov, S., Bartolovic, K., Komor, M., Kanz, L., Hofmann, W. K., Brummendorf, T. H., Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro.
Leukemia 2005, 19, 1483-1485.
Pubmed

Balabanov, S., Appel, S., Kanz, L., Brossart, P., Brummendorf, T. H.
Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.
Ann N Y Acad Sci2005, 1044, 168-177.
Pubmed

Appel, S., Balabanov, S., Brummendorf, T. H., Brossart, P.
Effects of imatinib on normal hematopoiesis and immune activation.
Stem Cells 2005, 23, 1082-1088.
Pubmed

2004

Zimmermann, U., Balabanov, S., Giebel, J., Teller, S., Junker, H., Schmoll, D., Protzel, C., Scharf, C., Kleist, B., Walther, R.
Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination.
Cancer Lett 2004, 209, 111-118.
Pubmed

 

 

Walther, R., Balabanov, S., Junker, H., Scharf, C., Zimmermann, U.
Proteome analysis of renal cell carcinoma to develop new strategies in diagnosis and therapy.
Int J Clin Pharmacol Ther 2004, 42, 635-636.
Pubmed

 

 

Dallmann, K., Junker, H., Balabanov, S., Zimmermann, U., Giebel, J., Walther, R.
Human agmatinase is diminished in the clear cell type of renal cell carcinoma.
Int J Cancer 2004, 108, 342-347.
Pubmed

Bartolovic, K., Balabanov, S*., Hartmann, U., Komor, M., Boehmler, A. M., Buhring, H. J., Mohle, R., Hoelzer, D., Kanz, L., Hofmann, W. K., Brummendorf, T. H.
Inhibitory effect of imatinib on normal progenitor cells in vitro.
Blood 2004, 103, 523-529. * joint first author
Pubmed

 

 

 

 

2003

Scheding, S., Ersoz, I., Hartmann, U., Bartolvic, K., Balabanov, S., Salama, A., Kanz, L., Brummendorf, T. H.
Peripheral blood cell telomere length measurements indicate that hematopoietic stem cell turnover is not significantly increased in whole blood and apheresis PLT donors.
Transfusion 2003, 43, 1089-1095.
Pubmed

Brummendorf, T. H., Ersoz, I., Hartmann, U., Bartolovic, K., Balabanov, S., Wahl, A., Paschka, P., Kreil, S., Lahaye, T., Berger, U., Gschaidmeier, H., Bokemeyer, C., Hehlmann, R., Dietz, K., Lansdorp, P. M., Kanz, L., Hochhaus, A.
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood2003, 101, 375-376.
Pubmed

Brummendorf, T. H., Ersoz, I., Hartmann, U., Balabanov, S., Wolke, H., Paschka, P., Lahaye, T., Berner, B., Bartolovic, K., Kreil, S., Berger, U., Gschaidmeier, H., Bokemeyer, C., Hehlmann, R., Dietz, K., Lansdorp, P. M., Kanz, L., Hochhaus, A.
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Ann N Y Acad Sci 2003, 996, 26-38.
Pubmed

 

 

2001

Schmoll, D., Balabanov, S., Schwarck, D., Burchell, A., Kleist, B., Zimmermann, U., Walther, R.
Differential expression of the subunits of the glucose-6-phosphatase system in the clear cell type of human renal cell carcinoma - no evidence for an overexpression of protein kinase B.
Cancer Lett 2001, 167, 85-90.
Pubmed

Balabanov, S., Zimmermann, U., Protzel, C., Scharf, C., Klebingat, K. J., Walther, R., Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis.
Eur J Biochem 2001, 268, 5977-5980.
Pubmed